Ensysce (ENSC) Investors - Your News Brief

Ensysce Biosciences logged a 12.0% change during today's morning session, and is now trading at a price of $0.8 per share. It was a relatively calm morning for the broader market, with the S&P 500 index moving 0.8% and the Nasdaq posted a 2.3% change.

Ensysce Biosciences shares moved -97.7% over the last 52 weeks, with a high of $35.6 and a low of $0.59. During this time, the stock lagged the S&P 500 index by -89.7%. As of January 2022, the company's 50-day average price is $1.23. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. The small-cap Healthcare company has 6 full time employees and is based in La Jolla, CA. Ensysce Biosciences has not offered any dividends in the last year.

The Company Does Not Yet Have Revenues:

2020-12-31 2021-12-31
Revenue (k) $0 $0
Earnings Per Share $0.05 -$29.6
EPS Growth n/a -59300.0%
Free Cash Flow (k) -$1,247 -$8,242
FCF Growth n/a -560.78%
LT Debt to Equity -0.0 -0.56

Ensysce Biosciences has negative earnings for the current period, so its trailing twelve month P/E ratio is not meaningful. Its forward P/E isn't meaningful either because its guidance EPS is -6.74.

Ensysce Biosciences Benefits From Positive Market Indicators:

3 analysts are following Ensysce Biosciences and have set target prices ranging from $5.3 to $8 per share. On average, they have given the company a rating of buy. At the current price of $0.8, ENSC is trading -87.36% away from its average analyst target price of $6.33 per share, implying an analyst consensus of strong upside potential for the stock.

The company has a very low short interest since 1.3% of the company's shares are tied to short positions. Institutions own 19.6% of Ensysce Biosciences's shares, while the insider ownership rate stands at 18.78%. The biggest shareholder is HG Vora Capital Management, LLC with a 2% stake in the company worth approximately $98,500.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.